These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21628707)

  • 1. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia.
    Aoyama N; Théberge J; Drost DJ; Manchanda R; Northcott S; Neufeld RW; Menon RS; Rajakumar N; Pavlosky WF; Densmore M; Schaefer B; Williamson PC
    Br J Psychiatry; 2011 Jun; 198(6):448-56. PubMed ID: 21628707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia.
    Théberge J; Williamson KE; Aoyama N; Drost DJ; Manchanda R; Malla AK; Northcott S; Menon RS; Neufeld RW; Rajakumar N; Pavlosky W; Densmore M; Schaefer B; Williamson PC
    Br J Psychiatry; 2007 Oct; 191():325-34. PubMed ID: 17906243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.
    Théberge J; Al-Semaan Y; Williamson PC; Menon RS; Neufeld RW; Rajakumar N; Schaefer B; Densmore M; Drost DJ
    Am J Psychiatry; 2003 Dec; 160(12):2231-3. PubMed ID: 14638596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers.
    Théberge J; Bartha R; Drost DJ; Menon RS; Malla A; Takhar J; Neufeld RW; Rogers J; Pavlosky W; Schaefer B; Densmore M; Al-Semaan Y; Williamson PC
    Am J Psychiatry; 2002 Nov; 159(11):1944-6. PubMed ID: 12411236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1H-MRS at 4 tesla in minimally treated early schizophrenia.
    Bustillo JR; Rowland LM; Mullins P; Jung R; Chen H; Qualls C; Hammond R; Brooks WM; Lauriello J
    Mol Psychiatry; 2010 Jun; 15(6):629-36. PubMed ID: 19918243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus.
    Yoo SY; Yeon S; Choi CH; Kang DH; Lee JM; Shin NY; Jung WH; Choi JS; Jang DP; Kwon JS
    Schizophr Res; 2009 Jun; 111(1-3):86-93. PubMed ID: 19406622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.
    Reid MA; White DM; Kraguljac NV; Lahti AC
    Schizophr Res; 2016 Feb; 170(2-3):341-50. PubMed ID: 26718333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy.
    Tandon N; Bolo NR; Sanghavi K; Mathew IT; Francis AN; Stanley JA; Keshavan MS
    Schizophr Res; 2013 Aug; 148(1-3):59-66. PubMed ID: 23791389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients.
    Stanley JA; Williamson PC; Drost DJ; Rylett RJ; Carr TJ; Malla A; Thompson RT
    Schizophr Bull; 1996; 22(4):597-609. PubMed ID: 8938914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic metabolite correlations with neuropsychological tests in first episode schizophrenia.
    Dempster K; Norman R; Théberge J; Densmore M; Schaefer B; Williamson P
    Psychiatry Res; 2015 Aug; 233(2):180-5. PubMed ID: 26163385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
    Szulc A; Galinska B; Tarasow E; Waszkiewicz N; Konarzewska B; Poplawska R; Bibulowicz D; Simonienko K; Walecki J
    Pharmacopsychiatry; 2011 Jun; 44(4):148-57. PubMed ID: 21710405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume.
    Stone JM; Day F; Tsagaraki H; Valli I; McLean MA; Lythgoe DJ; O'Gorman RL; Barker GJ; McGuire PK;
    Biol Psychiatry; 2009 Sep; 66(6):533-9. PubMed ID: 19559402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.
    Bustillo JR; Chen H; Jones T; Lemke N; Abbott C; Qualls C; Canive J; Gasparovic C
    JAMA Psychiatry; 2014 Mar; 71(3):265-72. PubMed ID: 24402128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania.
    Öngür D; Jensen JE; Prescot AP; Stork C; Lundy M; Cohen BM; Renshaw PF
    Biol Psychiatry; 2008 Oct; 64(8):718-726. PubMed ID: 18602089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.
    Iwata Y; Nakajima S; Plitman E; Caravaggio F; Kim J; Shah P; Mar W; Chavez S; De Luca V; Mimura M; Remington G; Gerretsen P; Graff-Guerrero A
    Biol Psychiatry; 2019 Apr; 85(7):596-605. PubMed ID: 30389132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients.
    Smesny S; Gussew A; Biesel NJ; Schack S; Walther M; Rzanny R; Milleit B; Gaser C; Sobanski T; Schultz CC; Amminger P; Hipler UC; Sauer H; Reichenbach JR
    Schizophr Res; 2015 Oct; 168(1-2):322-9. PubMed ID: 26255566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Spitzberg K; Kersting A; Arolt V; Heindel W; Pfleiderer B
    Schizophr Res; 2005 Mar; 73(2-3):153-7. PubMed ID: 15653258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia.
    Deicken RF; Zhou L; Schuff N; Weiner MW
    Schizophr Res; 1997 Oct; 27(1):65-71. PubMed ID: 9373896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex.
    Moore CM; Biederman J; Wozniak J; Mick E; Aleardi M; Wardrop M; Dougherty M; Harpold T; Hammerness P; Randall E; Lyoo IK; Renshaw PF
    J Affect Disord; 2007 Apr; 99(1-3):19-25. PubMed ID: 17005256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.